More joy for Lilly as dulaglutide gets EU go-ahead
This article was originally published in Scrip
Executive Summary
Just a week after the US FDA approved Lilly's new antidiabetic, Trulicity (dulaglutide), the EU's CHMP has granted a positive opinion for its use in type 2 diabetes.